NCT05903690View on ClinicalTrials.gov

Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

July 11, 2024

Study Completion Date

July 11, 2024

Conditions
Gene Mutation
Interventions
DRUG

RAG-17

RAG-17 60mg is used

Trial Locations (1)

100070

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
collaborator

Ractigen Therapeutics.

OTHER

lead

Beijing Tiantan Hospital

OTHER

NCT05903690 - Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation | Biotech Hunter | Biotech Hunter